Clinical and molecular characterization of FAP and SPP1 in colorectal cancer (CRC), CALGB (Alliance)/SWOG 80405 and real-world data. This is an ASCO Meeting Abstract from the 2025 ASCO ...

The ASCO/CAP panel noted that a result of IHC 0 may not mean that a cancer has no targetable HER2 protein present because HER2 assays are semiquantitative and were optimized to detect HER2 ...

Predicting mortality in upper gastrointestinal tract cancer using long short-term memory neural networks. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This ...

In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed the data – with the numbers every ...

and seems like a safer bet after a mid-stage readout at the ASCO-GI 2023 congress. Just a few weeks after its buy-in on the strength of data with zanidatamab in HER2-amplified biliary tract ...

is presenting clinical data from a completed Phase 1 trial evaluating a novel autologous HER2-targeted CAR-T therapy. The data presented today at the ASCO Gastrointestinal Cancers Symposium ...

at the 2025 ASCO Gastrointestinal Cancers Symposium. This investigational treatment demonstrated significant tumor response and a favorable safety profile, particularly in patients with HER2 ...

a clinical-stage biotechnology company discovering and developing cell and gene immunotherapies for solid and hematological malignancies, is presenting clinical data from a completed Phase 1 trial ...